We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Top Research Reports for Today: KHC, NKE, SYK & More
Read MoreHide Full Article
Tuesday May 2, 2017
Today's Research Daily features new research reports on 16 major stocks, including Kraft Heinz (KHC - Free Report) , Nike (NKE - Free Report) and Stryker (SYK - Free Report) .
Kraft Heinz shares have gained +2.4% year to date, outperforming the beleaguered Zacks categorized Food-Miscellaneous/Diversified industry which has lost -1.1% over the same period. Estimates have also remained stable ahead of the company's first quarter earnings release. Cost savings initiatives and strong gains from innovation continue to have a positive impact on the company’s performance.
The Zacks analyst also likes the company’s productivity improvement initiatives including zero-based budgeting; modernization and capability building. However, the company is experiencing top-line weakness over the past several quarters.
Soft spending by U.S. shoppers and shift in consumer preference toward natural and organic ingredients over packaged and processed food are hurting the company’s categories. Unfavorable currency translation continued to be a dampener for the segment through 2016 and is likely to hurt results in 2017 as well. (You can read the full research report on Kraft Heinz here.)
Shares of Nike have underperformed the Zacks Consumer Discretionary sector on a year-to-date basis, gaining +8.2% vs. +11.6% for the sector. But the Zacks analyst likes the company’s customer-centric approach, innovative products and strong brand portfolio. This, along with the company’s desire for increasing its global footprint, popularity and market share demonstrates its growth appetite.
These factors, along with SG&A leverage and ecommerce growth have helped Nike to beat earnings for 19 straight quarters now. However, Nike’s top-line fell prey to stiff competition and a tough retail backdrop in the last reported quarter. Persuaded by these factors, management provided soft sales growth outlook for fourth-quarter fiscal 2017. It also expects currency headwinds to linger and hurt revenues in the fiscal.
But Nike remains confident of driving sustainable and profitable capital efficient growth in the long term. Moreover, its shareholder-friendly moves bode well. (You can read the full research report on Nike here.)
Stryker shares have gained +17.4% over the last six months, outperforming the Zacks Medical Products industry, which has gained +11.2% over the same period. Stryker ended the first quarter of 2017 on a solid note, squarely beating expectations. The Zacks analyst thinks the company's innovative product pipeline will be a key catalyst in the near term.
Additionally, growing adoption of MAKO will drive sales in the orthopedic and reconstructive surgery market. Additionally, the acquisitions of Sage Products and Physio Control and the tie-up with Indo UK Institute of Health's Medicity Program are major positives.
On the flip side, China might prove to be a challenging market for the company. Coming to supply-side headwinds, the company has been grappling with issues in the spine business for a while. Additionally, challenging global economic conditions raise concerns. (You can read the full research report on Stryker here.)
Other noteworthy reports we are featuring today include DISH Network , TD Ameritrade (AMTD - Free Report) and Freeport-McMoRan (FCX - Free Report) .
Now See All Our Private Trades While today's Zacks Rank #1 new additions are being shared with the public, other trades are hidden from everyone but selected members. Would you like to peek behind the curtain and view them? Starting today, for the next month, you can follow all Zacks' private buys and sells in real time from value to momentum . . . from stocks under $10 to ETF and option moves . . . from insider trades to companies that are about to report positive earnings surprises (we've called them with 80%+ accuracy). You can even look inside portfolios so exclusive that they are normally closed to new investors. Click here for all Zacks trades >>
Mark Vickery
Senior Editor
Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here >>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Top Research Reports for Today: KHC, NKE, SYK & More
Tuesday May 2, 2017
Today's Research Daily features new research reports on 16 major stocks, including Kraft Heinz (KHC - Free Report) , Nike (NKE - Free Report) and Stryker (SYK - Free Report) .
Kraft Heinz shares have gained +2.4% year to date, outperforming the beleaguered Zacks categorized Food-Miscellaneous/Diversified industry which has lost -1.1% over the same period. Estimates have also remained stable ahead of the company's first quarter earnings release. Cost savings initiatives and strong gains from innovation continue to have a positive impact on the company’s performance.
The Zacks analyst also likes the company’s productivity improvement initiatives including zero-based budgeting; modernization and capability building. However, the company is experiencing top-line weakness over the past several quarters.
Soft spending by U.S. shoppers and shift in consumer preference toward natural and organic ingredients over packaged and processed food are hurting the company’s categories. Unfavorable currency translation continued to be a dampener for the segment through 2016 and is likely to hurt results in 2017 as well. (You can read the full research report on Kraft Heinz here.)
Shares of Nike have underperformed the Zacks Consumer Discretionary sector on a year-to-date basis, gaining +8.2% vs. +11.6% for the sector. But the Zacks analyst likes the company’s customer-centric approach, innovative products and strong brand portfolio. This, along with the company’s desire for increasing its global footprint, popularity and market share demonstrates its growth appetite.
These factors, along with SG&A leverage and ecommerce growth have helped Nike to beat earnings for 19 straight quarters now. However, Nike’s top-line fell prey to stiff competition and a tough retail backdrop in the last reported quarter. Persuaded by these factors, management provided soft sales growth outlook for fourth-quarter fiscal 2017. It also expects currency headwinds to linger and hurt revenues in the fiscal.
But Nike remains confident of driving sustainable and profitable capital efficient growth in the long term. Moreover, its shareholder-friendly moves bode well. (You can read the full research report on Nike here.)
Stryker shares have gained +17.4% over the last six months, outperforming the Zacks Medical Products industry, which has gained +11.2% over the same period. Stryker ended the first quarter of 2017 on a solid note, squarely beating expectations. The Zacks analyst thinks the company's innovative product pipeline will be a key catalyst in the near term.
Additionally, growing adoption of MAKO will drive sales in the orthopedic and reconstructive surgery market. Additionally, the acquisitions of Sage Products and Physio Control and the tie-up with Indo UK Institute of Health's Medicity Program are major positives.
On the flip side, China might prove to be a challenging market for the company. Coming to supply-side headwinds, the company has been grappling with issues in the spine business for a while. Additionally, challenging global economic conditions raise concerns. (You can read the full research report on Stryker here.)
Other noteworthy reports we are featuring today include DISH Network , TD Ameritrade (AMTD - Free Report) and Freeport-McMoRan (FCX - Free Report) .
Now See All Our Private Trades
While today's Zacks Rank #1 new additions are being shared with the public, other trades are hidden from everyone but selected members. Would you like to peek behind the curtain and view them? Starting today, for the next month, you can follow all Zacks' private buys and sells in real time from value to momentum . . . from stocks under $10 to ETF and option moves . . . from insider trades to companies that are about to report positive earnings surprises (we've called them with 80%+ accuracy). You can even look inside portfolios so exclusive that they are normally closed to new investors. Click here for all Zacks trades >>
Mark Vickery
Senior Editor
Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here >>>